Aldeyra The
$ 1.60
-5.88%
23 Apr - close price
- Market Cap 102,311,000 USD
- Current Price $ 1.60
- High / Low $ 1.70 / 1.57
- Stock P/E N/A
- Book Value 0.74
- EPS -0.56
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.59 %
- 52 Week High 6.17
- 52 Week Low 1.07
About
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.
Analyst Target Price
$7.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-11-05 | 2025-08-07 | 2025-04-30 | 2025-03-05 | 2024-11-01 | 2024-08-01 | 2024-05-02 | 2024-03-07 | 2023-11-03 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.11 | -0.13 | -0.16 | -0.17 | -0.27 | -0.25 | -0.28 | -0.14 | -0.08 | -0.14 | -0.15 | -0.27 |
| Estimated EPS | -0.155 | -0.245 | -0.2433 | -0.244 | -0.2173 | -0.25 | -0.14 | -0.11 | -0.14 | -0.24 | -0.31 | -0.29 |
| Surprise | 0.045 | 0.115 | 0.0833 | 0.074 | -0.0527 | 0 | -0.14 | -0.03 | 0.06 | 0.1 | 0.16 | 0.02 |
| Surprise Percentage | 29.0323% | 46.9388% | 34.2376% | 30.3279% | -24.2522% | 0% | -100% | -27.2727% | 42.8571% | 41.6667% | 51.6129% | 6.8966% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALDX
2026-04-24 14:50:01
The Schall Law Firm is notifying investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged securities fraud. The lawsuit claims that Aldeyra made false and misleading statements regarding inconsistent clinical trial results for its reproxalap drug candidate. Investors who purchased securities between November 3, 2023, and March 16, 2026, are encouraged to contact the firm by May 29, 2026, to potentially lead the lawsuit.
2026-04-24 01:11:01
Rosen Law Firm is encouraging investors of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) to join a securities class action lawsuit before the May 29, 2026, lead plaintiff deadline. The lawsuit alleges that Aldeyra made false or misleading statements regarding the inconsistent results of its reproxalap drug candidate clinical trials. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, may be entitled to compensation.
2026-04-23 07:00:00
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) and its officers. The lawsuit alleges that Aldeyra made false and misleading statements regarding inconsistent clinical trial results for its drug candidate, reproxalap, affecting investors who purchased securities between November 3, 2023, and March 16, 2026. Shareholders have until May 29, 2026, to request to be appointed as lead plaintiff.
2026-04-22 23:39:38
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) investors who suffered losses are reminded they have until May 29, 2026, to seek the role of lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that Aldeyra failed to disclose inconsistencies and unreliability in clinical trial results for its drug candidate, reproxalap, which led to a Complete Response Letter from the FDA and a significant stock price drop. Investors are encouraged to contact Kirby McInerney LLP to discuss their rights.
2026-04-22 12:00:00
Levi & Korsinsky, LLP has issued an investor alert regarding a securities fraud lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), naming Michael Alferi, Head of Finance, as an individual defendant. The lawsuit alleges that Alferi approved misleading disclosures concerning the efficacy and reliability of reproxalap clinical trial results, which led to a significant stock price drop after the FDA issued a Complete Response Letter rejecting the drug for dry eye disease. Investors who purchased shares between November 3, 2023, and March 16, 2026, and suffered losses are encouraged to seek to lead the class action by the May 29, 2026, deadline.
2026-04-22 03:09:16
Aldeyra Therapeutics announced that board member Martin J. Joyce will not seek re-election and will serve until his term concludes at the 2026 annual meeting of stockholders. The company clarified that Joyce's decision was not due to any disagreement, ensuring an orderly transition. This change in board composition is expected to be smooth and is not indicative of internal operational conflicts.
